Role of MDSCs and Cancer Stem Cells and Their Cross Talks in NSCLC

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Bordeaux

About this trial

Immunotherapy have revolutionized the field of oncology, but response rates are low and all patients relapse, due to cellular and soluble immunosuppressive mechanisms. MDSC are one of the most important immunosuppressive cells, that also harbour non immunologic functions, favouring cancer invasion. These non immunologic functions of MDSC in lung cancer will be better characterized. Indeed, cellular mechanisms will be analysed by in vitro studies, assessing the effect of immunosuppressive cells, provided by fresh tumor samples, on phenotype and functions of lung cancer cell lines. The aim of this study is to better characterize immunosuppressive landscape of NSCLC and mechanisms involved in their protumor functions.

Eligibility criteria

Qualifiers

consecutive patients

lung carcinoma surgically treated by surgery only

Disqualifiers

patient receiving chemotherapy, radiotherapy or immunotherapy in the neoadjuvant setting (all objectives)

patient with concomitant or previous cancer (in the 2 years)

Trial design

Treatments tested in this trial

  • Tumor samples

Treatment groups

10 Participants
are divided into 1 treatment group

Sponsors and collaborators